Live bacteria as anticancer agents and tumor-selective protein delivery vectors

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 2, 2002, Pages 194-199

  Bermudes, David ^a   Zheng, Li Mou ^a   King, Ivan C ^a  

^a Vion Pharmaceuticals Incorporated   (United States)

Author keywords

Bifidobacterium; Cancer therapy; Clostridium; Gene therapy; Salmonella; Vector

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; TAPET CD; UNCLASSIFIED DRUG; VNP 20009; YS 1629;

ANTINEOPLASTIC ACTIVITY; BIFIDOBACTERIUM LONGUM; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM HISTOLYTICUM; CLOSTRIDIUM SPOROGENES; DNA MODIFICATION; DNA VECTOR; DRUG SAFETY; DRUG SELECTIVITY; ESCHERICHIA COLI; GENE DELIVERY SYSTEM; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; REVIEW; SALMONELLA TYPHIMURIUM; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIAL PHYSIOLOGY; BIFIDOBACTERIUM; CLOSTRIDIUM; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PROTEINS; SALMONELLA;

EID: 0036489891     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. The treatment of malignant tumors by bacterial toxins as developed by the late William B Coley MD, reviewed in the light of modern research
2. A malignant pleural effusion infected with Salmonella enteritidis
3. Salmonellosis in patients with neoplastic disease
4. Abscess formation in a pheochromocytoma
5. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man
6. An endotoxin-induced serum factor that causes necrosis of tumors
7. Agonists and antagonists for lipopolysaccharide-induced cytokines
8. BCG in the treatment of superficial cancer of the bladder: A review
9. Prognosis of intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurement statistically weighted syndrome analysis
10. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: Development of a single-dose oral tetanus vaccine
11. Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine
12. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi
13. Characterization of aromatic- and purine-dependent Salmonella typhimurium attenuation, persistence, and ability to induce protective immunity in Balb/c mice
14. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection
15. Salmonella typhi vaccine strain CVD904 expressing the circumsporozoite protein of Plasmodium falciparum strain construction and safety and immunogenicity in humans
16. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers
17. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines
18. Selective delivery of antigens by recombinant bacteria
19. Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111
20. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers
21. Tumor-targeted Salmonella as a novel anticancer vector
22. Immunotherapy of a plasmacytoma with attenuated Salmonella
23. Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: A novel anti-tumor agent
24. Patterns of hepatic and splenic colonization by an attenuated strain of Salmonella typhimurium containing the gene for human interleukin-2: A novel anti-tumor agent
25. Lipid A mutant Salmonella with suppressed virulence and TNF-α induction retain tumor-targeting in vivo
26. VNP20009, a genetically modified Salmonella typhimurium for treatment of solid tumors
27. Genetically modified Salmonella typhimurium inhibited growth of primary tumors and metastase
28. Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector
29. Barriers to drug delivery in solid tumors
30. Haemodynamic and transport barriers to the treatment of solid tumors
31. Salmonella-based tumor-targeted cancer therapy: Tumor amplified protein expression therapy (TAPET) for diagnostic imaging
32. Genetically armed Salmonella typhimurium delivered therapeutic gene and inhibited tumor growth in preclinical models
33. Tumor-directed delivery and amplification of tumor-necrosis factor-α (TNF) by attenuated Salmonella typhimurium
34. A strain of Salmonella typhimurium VNP20009 expressing an anti-angiogenic peptide from platelet factor-4 has enhanced anti-tumor activity
35. Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium
36. Evaluation of the acute and subchronic toxic effects in mice, rats, and monkeys of the genetically engineered and Escherichia coli cytosine deaminase gene-incorporated Salmonella strain, TAPET-CD, being developed as an antitumor agent
37. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001
38. 2 tension measurements
39. Effect of histolyticus infection and toxin on transplantable mouse tumors
40. Oncolysis by Clostridia V transplanted tumors of the hamster
41. Oncolysis by Clostridia IV effect of nonpathogenic Clostridial spores in normal and pathological tissues
42. Clostridial oncolysis in man
43. Anaerobic bacteria as a delivery system for cancer gene therapy: In vitro activation of 5-fluorocytosine by genetically engineered clostridia
44. Anaerobic bacteria as a gene delivery system to tumors
45. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment
46. Chemotherapeutic tumor targeting using clostridial spores
47. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum
48. Increasing specificity of anti-tumor therapy: Cytotoxic protein delivery by non-pathogenic Clostridia under regulation of radio-induced promoters
49. Radio-responsive recA promoter significantly increases TNF-α production in recombinant Clostridia after 2 Gy irradiation
50. Combination bacteriolytic therapy for the treatment of experimental tumors
51. Analysis of antitumor properties of effector cells stimulated with a cell wall preparation (WPG) of Bifidobacterium infantis
52. Antitumor activity of Bifidobacterium spp. isolated from a healthy Korean
53. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration
54. Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors
55. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors